47 results about "Transcription factor activity" patented technology

The invention provides an application of a type of berbamine derivatives and salts thereof in the preparation of drugs for the treatment of tumors, which is mainly applied in the preparation of the drugs for the prevention and treatment of nuclear transcription factor NF-kBp65 activity-related diseases and BCR/ABL transcription activity-related diseases. The drugs are combined and prepared by the compounds of the invention and one or more pharmaceutically acceptable excipients. The preparation forms comprise solid preparations, semi-solid preparations or liquid preparations. The type of berbamine derivatives and the salts thereof provided by the invention have broader and stronger anti-leukemia and anti-solid-tumor activity, the tumors proved to be sensitive are leukemia, multiple myeloma, liver cancer, osteosarcoma and breast cancer; the toxicity and the side effects are lighter. An in vitro cell culture system and animal experiments confirm that the berbamine derivatives and the salts thereof have no significant toxicity or side effects to the growth of normal human hematopoietic cells and experimental animals under the anti-tumor dosage, which are superior to the commonly used chemotherapy drugs.

Embodiments of the invention provides, among other things, methods for identifying agents that inhibit oncogenic transcription factors, induce apoptosis, inhibit the growth of transformed cells and cancer cells, and potentiate the effects of other agents that induce apoptosis and that inhibit the growth of transformed cells and cancer cells. Embodiments of the invention further provide compositions useful for the same comprising an agent the inhibits one or more oncogenic transcription factors and an agent that induces apoptosis, particular compositions wherein the apoptotic effect of the combination is greater than either agent by itself. Embodiments of the invention further provide for the use of such agents and compositions to treat cancer. In illustrative embodiments the agents that inhibit transcription factor activity are thiazole antibiotics, such as Siomycin and thiostrepton, and the apoptosis inducing agent is a member of the TNF ligand superfamily, such as TNF-alpha. In illustrative embodiments the cancers are those in which both the FoxM1 and the NF-kB oncogenic pathways are activated.

The invention discloses the influence of melatonin on hulless oat seedlings under drought stress, and an application of melatonin to promotion of transcription factor activity in eukaryotic organismsunder drought conditions. The invention lays a foundation for exploring possible actions of melatonin in an anti-oxidation and defense system of a hulless oat drought resistance mechanism.

This invention provides an implant that enable satisfactory bone/cartilage regeneration by allowing sustained release of virus vectors carrying the transcription factor gene in vivo and persistent maintenance of transcription factor activity.

The invention discloses application of a 4N heterocyclic compound as an inhibitor for Th17 cell differentiation. In virtue of a luciferase activity screening system based on the activity of transcription factors, it is found that the 4N heterocyclic compound with a general formula as described in the specification has capability in inhibiting the key transcription factor ROR gamma t of Th17 cell differentiation and the inhibition capability EC50 is in a range of 0.2 to 1.5 [mu]M. In-vitro Th17 cell differentiation experiments prove that the 4N heterocyclic compound is capable of inhibiting Th17 differentiation, including substantially reducing the transcription expression of ROR gamma t, inhibiting the transcription expression of the effector molecules IL17A and IL17F of Th17 and obviously inhibiting the secretion level of IL17A cytokines in a culture. The 4N heterocyclic compound is expected to be developed into a drug used for treating autoimmune diseases, especially psoriasis, systematic lupus erythematosus, multiple sclerosis, rheumatoid arthritis, asthma or inflammatory intestinal diseases.

The invention discloses a cell signal transduction activity detection method based on a tetrahedral DNA nano-material, which comprises a specific DNA binding sequence of a transcription factor capable of characterizing signal transduction activity to be detected and a fluorescent label, when a target transcription factor is bound with TDNs, a fluorophore and a quenching group are prevented from approaching, and when the target transcription factor is bound with TDNs, the signal transduction activity to be detected is detected. Therefore, the transcription factor activity can be analyzed by detecting the fluorophore. The method is simple, convenient and efficient, qualitative, quantitative and imaging analysis can be synchronously completed, and the operation time is short. In addition, the synthesis method of the tetrahedral DNA nano material is simple and convenient, has good reproducibility, can be flexibly designed according to target molecules to be detected, and has strong universality.

The invention provides a method for detecting the expression quantity of HOXD9 after peripheral nerve injury. The method comprises the following steps: (1) separating dorsal root ganglion neuron nucleoproteins at different time points after sciatic nerve injury of a rat, performing transcription factor activity detection, and determining the expression quantity change trend of a transcription factor HOXD9 in the nerve regeneration process; (2) observing the expression quantity and the expression trend of related messenger RNA results of HOXD9 by applying a PCR technology; (3) displaying intracellular localization of the HOXD9 in an DRG neuron by adopting an immunofluorescence staining technology; and (4) counting the HOXD9 fluorescence intensity change trends at different time points afterthe sciatic nerve injury, and enabling the fluorescence intensity to be the highest on the third day and to be consistent with a result trend obtained by a PCR experiment. The expression quantity change of HOXD9 after peripheral nerve injury is clarified, and the regulation effect of THE HOXD9 on neuron axon regeneration is discovered.

The invention provides a fluorescent biosensor and method for detecting a transcription factor and an application of the fluorescent biosensor and belongs to the technical field of detection analysis.The invention provides a two-way EXPAR and endonuclease IV-assisted circulatory digestion signal probe-based super-sensitive fluorescence strategy for detecting the transcription factor. Compared with conventional EXPAR, two-way EXPAR can initiate extension reaction in two directions to generate abundant trigger signals, so as to improve the amplification efficiency. The method is simple in operation, economic, high in sensitivity, low in background and good in specificity, and super-sensitive detection for the activity of the transcription factor in cells can be achieved by using the method,therefore, the method has good practical application value.

Provided herein is, inter alia, methods and compositions useful in therapeutic interrogation of complex physiologic pathways by massively parallel and permissive transcriptional screening. Thus, methods and compositions are provided herein that are useful for high-throughput functional analysis of complex, transcriptionally regulated physiological pathways. While examples are provided relating to nuclear receptors, the methods and composition can be generalized and applied to any class of transcription factor or any class of gene product that can regulate the activity of transcription. For example, in addition to nuclear receptors, the methods and compositions provided herein are generally applicable to all known transcription factors and any gene encoded product that modulates said transcription factor activity. Moreover, data obtained through the methods provided herein are directly comparable thereby facilitating high-throughput functional analysis.